BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 31704134)

  • 1. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
    Chawla S; Blay JY; Rutkowski P; Le Cesne A; Reichardt P; Gelderblom H; Grimer RJ; Choy E; Skubitz K; Seeger L; Schuetze SM; Henshaw R; Dai T; Jandial D; Palmerini E
    Lancet Oncol; 2019 Dec; 20(12):1719-1729. PubMed ID: 31704134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.
    Chawla S; Henshaw R; Seeger L; Choy E; Blay JY; Ferrari S; Kroep J; Grimer R; Reichardt P; Rutkowski P; Schuetze S; Skubitz K; Staddon A; Thomas D; Qian Y; Jacobs I
    Lancet Oncol; 2013 Aug; 14(9):901-8. PubMed ID: 23867211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
    Palmerini E; Seeger LL; Gambarotti M; Righi A; Reichardt P; Bukata S; Blay JY; Dai T; Jandial D; Picci P
    BMC Cancer; 2021 Jan; 21(1):89. PubMed ID: 33482769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
    Palmerini E; Chawla NS; Ferrari S; Sudan M; Picci P; Marchesi E; Leopardi MP; Syed I; Sankhala KK; Parthasarathy P; Mendanha WE; Pierini M; Paioli A; Chawla SP
    Eur J Cancer; 2017 May; 76():118-124. PubMed ID: 28324746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab Treatment for Giant Cell Tumor of the Spine Including the Sacrum.
    Bukata SV; Blay JY; Rutkowski P; Skubitz K; Henshaw R; Seeger L; Dai T; Jandial D; Chawla S
    Spine (Phila Pa 1976); 2021 Mar; 46(5):277-284. PubMed ID: 33038190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.
    Rutkowski P; Ferrari S; Grimer RJ; Stalley PD; Dijkstra SP; Pienkowski A; Vaz G; Wunder JS; Seeger LL; Feng A; Roberts ZJ; Bach BA
    Ann Surg Oncol; 2015 Sep; 22(9):2860-8. PubMed ID: 26033180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.
    Coleman R; Finkelstein DM; Barrios C; Martin M; Iwata H; Hegg R; Glaspy J; Periañez AM; Tonkin K; Deleu I; Sohn J; Crown J; Delaloge S; Dai T; Zhou Y; Jandial D; Chan A
    Lancet Oncol; 2020 Jan; 21(1):60-72. PubMed ID: 31806543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
    Perrin DL; Visgauss JD; Wilson DA; Griffin AM; Abdul Razak AR; Ferguson PC; Wunder JS
    Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.
    Ueda T; Morioka H; Nishida Y; Kakunaga S; Tsuchiya H; Matsumoto Y; Asami Y; Inoue T; Yoneda T
    Ann Oncol; 2015 Oct; 26(10):2149-54. PubMed ID: 26205395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab in patients with giant-cell tumor of bone in Norway: results from a nationwide cohort.
    Boye K; Jebsen NL; Zaikova O; Knobel H; Løndalen AM; Trovik CS; Monge OR; Hall KS
    Acta Oncol; 2017 Mar; 56(3):479-483. PubMed ID: 28105885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
    Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
    Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
    Zhang RZ; Ma TX; Qi DW; Zhao M; Hu T; Zhang GC
    Orthop Surg; 2019 Dec; 11(6):1101-1108. PubMed ID: 31762217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial.
    Yue J; Sun W; Li S
    J Bone Oncol; 2022 Aug; 35():100441. PubMed ID: 35800292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial.
    Rutkowski P; Gaston L; Borkowska A; Stacchiotti S; Gelderblom H; Baldi GG; Palmerini E; Casali P; Gronchi A; Parry M; Campanacci DA; Scoccianti G; Wagrodzki M; Ferrari S; Dijkstra S; Pieńkowski A; Grimer R
    Eur J Surg Oncol; 2018 Sep; 44(9):1384-1390. PubMed ID: 29650420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis.
    Reddy K; Ramirez L; Kukreja K; Venkatramani R
    J Pediatr Hematol Oncol; 2021 Mar; 43(2):e215-e218. PubMed ID: 31714440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative Denosumab plus Surgery in the Management of Giant Cell Tumor of Bone: A Comprehensive Narrative Literature Review.
    Abu-Zaid A; Alaqaili SI; Ahmad SO; Bin Hazzaa I; Alharbi H
    Gulf J Oncolog; 2019 May; 1(30):67-75. PubMed ID: 31242985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?
    Scoccianti G; Totti F; Scorianz M; Baldi G; Roselli G; Beltrami G; Franchi A; Capanna R; Campanacci DA
    Clin Orthop Relat Res; 2018 Sep; 476(9):1783-1790. PubMed ID: 30778015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current concepts in the treatment of giant cell tumour of bone.
    van der Heijden L; Dijkstra S; van de Sande M; Gelderblom H
    Curr Opin Oncol; 2020 Jul; 32(4):332-338. PubMed ID: 32541321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial.
    Lipplaa A; Kroep JR; van der Heijden L; Jutte PC; Hogendoorn PCW; Dijkstra S; Gelderblom H
    Oncologist; 2019 Jul; 24(7):889-e421. PubMed ID: 31040253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Radiologic Response of Central Giant Cell Granuloma to Denosumab: A 6-Year Prospective Observational Study.
    Rhou YJJ; Wang CJ; Nguyen M; Vanderniet JA; Munns CF; Coleman H; Kim J; Holmes-Walker DJ; Lim L; Girgis CM
    Calcif Tissue Int; 2022 Apr; 110(4):464-474. PubMed ID: 35088118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.